Figure 4.

A series of approaches has been developed to block γ chain (γc) cytokine, Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling in T-cell malignancies and autoimmune disorders. Such therapeutic approaches include targeting the γc cytokines directly, agents that block cytokine receptor interactions, and JAK kinase inhibitors. H9-RETR, the RETR mutant of H9 super-IL-2. (This figure was previously published as Figure 4 in Waldmann et al. 2017. It is now reproduced with permission.)